TACSTD2 and posterior cortical atrophy: Among these, sacituzumab govitecan (SG) is a first-in-class ADC consisting of a humanized monoclonal antibody directed against TROP-2, which is expressed in PCa, and conjugated with SN-38, the active metabolite of irinotecan.